Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren

doi:10.1016/j.vaccine.2009.05.018

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Lindvi Gudmundsdotter^*
, Charlotta Nilsson
, Andreas Brave
, Bo Hejdeman
, Patricia Earl
, Bernard Moss
, Merlin Robb
, Josephine Cox
, Nelson Michael
, Mary Marovich
, Gunnel Biberfeld
, Eric Sandström
, Britta Wahren

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

Original language	English
Pages (from-to)	4468-4474
Number of pages	7
Journal	Vaccine
Volume	27
Issue number	33
DOIs	https://doi.org/10.1016/j.vaccine.2009.05.018
State	Published - 16 Jul 2009

Keywords

HIV-1 vaccine
Modified Vaccinia virus Ankara (MVA)
Pre-existing immunity

Access to Document

10.1016/j.vaccine.2009.05.018

Cite this

Gudmundsdotter, L., Nilsson, C., Brave, A., Hejdeman, B., Earl, P., Moss, B., Robb, M., Cox, J., Michael, N., Marovich, M., Biberfeld, G., Sandström, E., & Wahren, B. (2009). Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine, 27(33), 4468-4474. https://doi.org/10.1016/j.vaccine.2009.05.018

@article{6b34c52aa52148e3adef3bbe35fe75ef,

title = "Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity",

abstract = "The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.",

keywords = "HIV-1 vaccine, Modified Vaccinia virus Ankara (MVA), Pre-existing immunity",

author = "Lindvi Gudmundsdotter and Charlotta Nilsson and Andreas Brave and Bo Hejdeman and Patricia Earl and Bernard Moss and Merlin Robb and Josephine Cox and Nelson Michael and Mary Marovich and Gunnel Biberfeld and Eric Sandstr{\"o}m and Britta Wahren",

note = "Funding Information: This study was supported by the European Union (INCO-DEV A4 ICFP501A4PR03, AVIP 503487); Swedish International Development Cooperation Agency (Sida); Department of Research Cooperation (SAREC) (SWE-2004-120, HIV2004-000809, 2004:813); Swedish Research Council (Vetenskapsr{\aa}det, K2004-16x-07743-19); L{\"a}kare mot AIDS Forskningsfond (04-050301 and 01-051101). Construction of the HIV-1 modified vaccinia virus Ankara was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health and the US Military HIV Research Program. The production costs were funded by the US Military HIV Research Program, Walter Reed Army Institute of Research.",

year = "2009",

month = jul,

day = "16",

doi = "10.1016/j.vaccine.2009.05.018",

language = "English",

volume = "27",

pages = "4468--4474",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "33",

}

Gudmundsdotter, L, Nilsson, C, Brave, A, Hejdeman, B, Earl, P, Moss, B, Robb, M, Cox, J, Michael, N, Marovich, M, Biberfeld, G, Sandström, E & Wahren, B 2009, 'Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity', Vaccine, vol. 27, no. 33, pp. 4468-4474. https://doi.org/10.1016/j.vaccine.2009.05.018

TY - JOUR

T1 - Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

AU - Gudmundsdotter, Lindvi

AU - Nilsson, Charlotta

AU - Brave, Andreas

AU - Hejdeman, Bo

AU - Earl, Patricia

AU - Moss, Bernard

AU - Robb, Merlin

AU - Cox, Josephine

AU - Michael, Nelson

AU - Marovich, Mary

AU - Biberfeld, Gunnel

AU - Sandström, Eric

AU - Wahren, Britta

N1 - Funding Information: This study was supported by the European Union (INCO-DEV A4 ICFP501A4PR03, AVIP 503487); Swedish International Development Cooperation Agency (Sida); Department of Research Cooperation (SAREC) (SWE-2004-120, HIV2004-000809, 2004:813); Swedish Research Council (Vetenskapsrådet, K2004-16x-07743-19); Läkare mot AIDS Forskningsfond (04-050301 and 01-051101). Construction of the HIV-1 modified vaccinia virus Ankara was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health and the US Military HIV Research Program. The production costs were funded by the US Military HIV Research Program, Walter Reed Army Institute of Research.

PY - 2009/7/16

Y1 - 2009/7/16

N2 - The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

AB - The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus.

KW - HIV-1 vaccine

KW - Modified Vaccinia virus Ankara (MVA)

KW - Pre-existing immunity

UR - https://www.scopus.com/pages/publications/67649338409

U2 - 10.1016/j.vaccine.2009.05.018

DO - 10.1016/j.vaccine.2009.05.018

M3 - Article

C2 - 19450644

AN - SCOPUS:67649338409

SN - 0264-410X

VL - 27

SP - 4468

EP - 4474

JO - Vaccine

JF - Vaccine

IS - 33

ER -

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

Abstract

Keywords

Access to Document

Fingerprint

Cite this